Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Papp

Showing results (391-400 of 406) with videos related to

Pageof 41
Sort By:
Journal of the American Academy of Dermatology|January 22, 2024
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trialAndrew Blauvelt, Zoe D Draelos, Linda Stein Gold, et al.
Lancet (London, England)|May 23, 2021
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trialsEmma Guttman-Yassky, Henrique D Teixeira, Eric L Simpson, et al.
The British Journal of Dermatology|June 6, 2023
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb studyLeon H Kircik, Javier Alonso-Llamazares, Neal Bhatia, et al.
The New England Journal of Medicine|June 15, 2016
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque PsoriasisKenneth B Gordon, Andrew Blauvelt, Kim A Papp, et al.
JAMA Dermatology|September 18, 2024
Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical TrialsEric L Simpson, Lawrence F Eichenfield, Javier Alonso-Llamazares, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 13, 2025
Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension studyMatthias Augustin, Marie Tauber, Robert Sidbury, et al.
Journal of the American Academy of Dermatology|March 31, 2024
Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trialLinda Stein Gold, David N Adam, Lorne Albrecht, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|January 10, 2025
Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension TrialEric L Simpson, Lawrence F Eichenfield, Kim A Papp, et al.
The Journal of Rheumatology|June 13, 2017
Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily PracticeDafna D Gladman, Yves Poulin, Karen Adams, et al.
American Journal of Clinical Dermatology|September 3, 2025
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 WeeksAlan D Irvine, Vimal H Prajapati, Emma Guttman-Yassky, et al.
Pageof 41

Showing results (391-400 of 406) with videos related to

Sort By:
Pageof 41
Journal of the American Academy of Dermatology|January 22, 2024
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trialAndrew Blauvelt, Zoe D Draelos, Linda Stein Gold, et al.
Lancet (London, England)|May 23, 2021
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trialsEmma Guttman-Yassky, Henrique D Teixeira, Eric L Simpson, et al.
The British Journal of Dermatology|June 6, 2023
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb studyLeon H Kircik, Javier Alonso-Llamazares, Neal Bhatia, et al.
The New England Journal of Medicine|June 15, 2016
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque PsoriasisKenneth B Gordon, Andrew Blauvelt, Kim A Papp, et al.
JAMA Dermatology|September 18, 2024
Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical TrialsEric L Simpson, Lawrence F Eichenfield, Javier Alonso-Llamazares, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 13, 2025
Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension studyMatthias Augustin, Marie Tauber, Robert Sidbury, et al.
Journal of the American Academy of Dermatology|March 31, 2024
Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trialLinda Stein Gold, David N Adam, Lorne Albrecht, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|January 10, 2025
Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension TrialEric L Simpson, Lawrence F Eichenfield, Kim A Papp, et al.
The Journal of Rheumatology|June 13, 2017
Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily PracticeDafna D Gladman, Yves Poulin, Karen Adams, et al.
American Journal of Clinical Dermatology|September 3, 2025
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 WeeksAlan D Irvine, Vimal H Prajapati, Emma Guttman-Yassky, et al.
Pageof 41